Jean George - Catabasis Pharmaceuticals Director
Director
Ms. Jean George is an Independent Director of Catabasis Pharmaceuticals, Inc. Since February 2002, she was a Managing Director at Advanced Technology Ventures, a VC fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms. George has served as Managing Director at Lightstone Ventures, a VC firm. Ms. George currently serves as a member of the board of directors of the public companies Acceleron Pharma and Calithera Biosciences, and previously served as a member of the board of directors of Portola Pharmaceuticals from 2005 to 2013 and of Zeltiq Aesthetics from 2005 to 2015 since 2013.
| Age | 59 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 617 349 1971 |
| Web | http://www.catabasis.com |
Catabasis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (20.32) % which means that it has lost $20.32 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (210.26) %, meaning that it created substantial loss on money invested by shareholders. Catabasis Pharmaceuticals' management efficiency ratios could be used to measure how well Catabasis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 713 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Catabasis Pharmaceuticals has a current ratio of 34.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Catabasis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Catabasis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Catabasis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Catabasis to invest in growth at high rates of return. When we think about Catabasis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Moskow | Discover Financial Services | 83 | |
| Thomas Scannapieco | Univest Pennsylvania | 64 | |
| Alfredo Huallem | Gerdau SA ADR | 66 | |
| John Owen | Discover Financial Services | 63 | |
| Hironaga Fukuo | Chiba Bank Ltd | N/A | |
| Hiroshi Seki | Chiba Bank Ltd | N/A | |
| Toru Nomura | Chiba Bank Ltd | 57 | |
| Yuichi Katayama | Chiba Bank Ltd | N/A | |
| Junya Wakabayashi | Chiba Bank Ltd | N/A | |
| Shigenobu Sadachi | Chiba Bank Ltd | N/A | |
| Paul Shelly | Univest Pennsylvania | 70 | |
| Tench Coxe | Artisan Partners Asset | 62 | |
| Sherry Cladouhos | Glacier Bancorp | 65 | |
| William Morral | Univest Pennsylvania | 70 | |
| Michael Turner | Univest Pennsylvania | 61 | |
| Margaret Zook | Univest Pennsylvania | 68 | |
| Howard Liszt | Mill City Ventures | 67 | |
| Richard Lenny | Discover Financial Services | 64 | |
| Jeffrey Joerres | Artisan Partners Asset | 61 | |
| Kazuyoshi Fukushima | Chiba Bank Ltd | N/A | |
| George Sutton | Glacier Bancorp | 72 | |
Management Performance
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 |
Catabasis Pharmaceuticals Leadership Team
Elected by the shareholders, the Catabasis Pharmaceuticals' board of directors comprises two types of representatives: Catabasis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catabasis. The board's role is to monitor Catabasis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catabasis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catabasis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Director | ||
| Angelika Fretzen, Senior Vice President - Product Development | ||
| Gregg Lapointe, Director | ||
| Rick Modi, Chief Business Officer | ||
| Joanne Donovan, Chief Medical Officer | ||
| Deirdre Cunnane, Senior Vice President General Counsel | ||
| Michael Jirousek, Co-Founder and Member of Scientific Advisory Board | ||
| Michael Kishbauch, Director | ||
| Edward Hibben, Chief Business Officer | ||
| Joanne Beck, Director | ||
| Ian Sanderson, CFO, Treasurer | ||
| Burt Adelman, Director | ||
| Deirdre JD, Sr. VP and General Counsel | ||
| Kenneth Bate, Director | ||
| Hugh Cole, Director | ||
| Jill Milne, Co-Founder, CEO and President and Director | ||
| Andrea Matthews, IR Contact Officer | ||
| Nicholas Galakatos, Director | ||
| Ron Laufer, Director | ||
| Michael Ross, Chairman of the Board | ||
| Andrew Nichols, Sr. VP of Research | ||
| Ted Hibben, Sr. VP of Corporate Devel. |
Catabasis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catabasis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 | |||
| Current Valuation | 58.17 M | |||
| Shares Outstanding | 76.95 M | |||
| Shares Owned By Insiders | 0.03 % | |||
| Shares Owned By Institutions | 54.77 % | |||
| Number Of Shares Shorted | 96.27 K | |||
| Price To Earning | (1.24) X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 258.49 X |
Pair Trading with Catabasis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catabasis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catabasis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Catabasis Stock
If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |